Orthofix gets US FDA approval for foot bone implant
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Orthofix International NV said the U.S. Food and Drug Administration granted 510(k) clearance to its G-Beam fusion beaming system to treat Charcot foot, a condition where the bones in the foot weaken and collapse.
The Lewisville, Texas-based device-maker said the G-Beam devices can be implanted in the medial and lateral columns of the foot to provide alignment, stabilization and fixation.
